Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation

Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation

Abstract Immune checkpoint inhibitor (ICI)-based immunotherapy has emerged as the most promising strategy for hepatocellular carcinoma (HCC) downstaging prior to liver transplantation (LT). However, further evidence is required to assess the feasibility and safety of pretransplant ICI exposure. We r...

Full description

Saved in:
Bibliographic Details
Main Authors: Xinjun Lu, Qi Zhu, Junfeng Cai, Zuozhong Yang, Guangxiang Gu, Li Pang, Mingye Su, Fapeng Zhang, Haoming Lin, Wenrui Wu, Leibo Xu, Chao Liu
Format: Article
Language:English
Published: Springer 2024-11-01
Series:Cancer Immunology, Immunotherapy
Subjects:
HCC
Liver transplantation
Immune checkpoint inhibitor
Acute rejection
MVI
Online Access:https://doi.org/10.1007/s00262-024-03853-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-024-03853-9

Similar Items